Rapport Therapeutics, Inc. 8-K

What Happened
Rapport Therapeutics, Inc. (RAPP) filed an 8-K reporting the results of its Annual Meeting of Stockholders held on June 10, 2026. As of the record date (April 14, 2026) there were 47,807,623 shares outstanding and entitled to vote. Stockholders elected James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors (each to serve until the 2029 annual meeting) and ratified PricewaterhouseCoopers LLP (PwC) as the company’s independent registered public accounting firm for fiscal year 2026.

Key Details

• Record date and shares: 47,807,623 shares outstanding as of April 14, 2026.
• Director election vote totals:
  • James Healy: For 41,762,713; Withheld 587,163; Broker non-votes 1,983,035.
  • Robert J. Perez: For 37,592,089; Withheld 4,757,787; Broker non-votes 1,983,035.
  • Raymond Sanchez: For 41,754,131; Withheld 595,745; Broker non-votes 1,983,035.
• Auditor ratification vote (PwC): For 44,255,547; Against 57,445; Abstain 19,919.
• No other matters were submitted or voted on at the Annual Meeting.

Why It Matters
The filing confirms board composition and auditor continuity—two governance items investors watch for oversight and financial reporting stability. The director elections establish the Class II board seats through the 2029 meeting, and ratification of PwC confirms the accounting firm that will audit Rapport’s 2026 financial statements. Vote tallies (including broker non-votes) show the level of shareholder support and participation for these governance actions.